Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: An observational study, plus systematic review and meta-analysis

Alimentary Pharmacology and Therapeutics

Volumn 43, Issue 8, 2016, Pages 910-923

  Kennedy, Nicholas A ⁱ   Warner, Ben ^j   Johnston, Emma L ^j   Flanders, Lucy ^j   Hendy, Philip ^l   Ding, Nik S ^l   Harris, Richard ^m   Fadra, Adam S ⁿ   Basquill, Catriona ⁱ   Lamb, Christopher A ^o   Cameron, Fiona L ^p,q   Murray, Charles D ^r   Parkes, Miles ^s   Gooding, Ian ^t   Ahmad, Tariq ^u   Gaya, Daniel R ^v   Mann, Steve ^w   Lindsay, James O ⁿ   Gordon, John ^m   Satsangi, Jack ⁱ   Hart, Ailsa ^l   McCartney, Sara ^k   Irving, Peter ^j   Lees, Charlie W ⁱ   Basavaraju, Umesh ^x   Christodoulou, Christos ^s   Cummings, Fraser ^y   Grieveson, Kay ^r   Johnston, Matthew ^z   Lal, Simon ^aa   Lithgo, Karen ^z   Lockett, Melanie ^ab   Maggs, Daniel ^ab   Mansfield, John ^ac   Mason, Joy ^t   Nowell, Emma ^ad   Russell, Richard K ^q   Singh, Abhey ^u   Stansfield, Catherine ^aa   Thomson, John ^x   Wilson, David C ^p   more..

^a Edinburgh   (United Kingdom)

^b London   (United Kingdom)

^c NHS Foundation Trust ^*  (United Kingdom)

^d University in Newcastle upon Tyne   (United Kingdom)

^e Glasgow   (United Kingdom)

^f Cambridge ESOL   (United Kingdom)

^g Royal Hospital for Sick Children ^*  (United Kingdom)

^h Exeter Medical School   (United Kingdom)

ⁱ WESTERN GENERAL HOSPITAL   (United Kingdom)

^j GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^k UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^l ST MARK S HOSPITAL   (United Kingdom)

^m ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

ⁿ ROYAL LONDON HOSPITAL   (United Kingdom)

^o NEWCASTLE UNIVERSITY   (United Kingdom)

^p ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^q UNIVERSITY OF EDINBURGH   (United Kingdom)

^r UNIVERSITY COLLEGE LONDON   (United Kingdom)

^s ADDENBROOKE S HOSPITAL   (United Kingdom)

^t IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^u ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^v GLASGOW ROYAL INFIRMARY   (United Kingdom)

^w ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^x ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^y UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^z LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

^aa NHS Foundation Trust   (United Kingdom)

^ab NORTH BRISTOL NHS TRUST   (United Kingdom)

^ac ROYAL VICTORIA INFIRMARY   (United Kingdom)

^ad HAIRMYRES HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CALGRANULIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DRUG RESPONSE; DRUG WITHDRAWAL; ENDOSCOPY; FECES; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNITED KINGDOM; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLITIS, ULCERATIVE; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; TIME FACTOR;

ADALIMUMAB; ADULT; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLIXIMAB; MALE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84959094475     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13547     Document Type: Article

References (31)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
3. Colombel JF, Sandborn WJ, Rutgeerts P, et al,. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
4. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al,. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-50.
5. Dignass A, Van Assche G, Lindsay JO, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
6. Dignass A, Lindsay JO, Sturm A, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: current management. J Crohns Colitis 2012; 6: 991-1030.
7. Joint Formulary Committee. British National Formulary [Internet], 2016. Available at: http://www.medicinescomplete.com (accessed 11 January 2016).
8. Theede K, Dahlerup JF, Fallingborg J, et al,. Biologic therapy in inflammatory bowel disease. Dan Med J 2013; 60: 1-9.
9. Pariente B, Laharie D,. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2014; 40: 338-53.
10. Louis E, Belaiche J, Reenaers C,. Anti-TNF and Crohn's disease: when should we stop? Curr Drug Targets 2010; 11: 148-51.
11. Van Assche G, Lewis JD, Lichtenstein GR, et al,. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organisation: safety. AmJ Gastroenterol 2011; 106: 1594-602.
12. Sorrentino D, Nash P, Viladomiu M, Hontecillas R, Bassaganya-Riera J,. Stopping Anti-TNF Agents in Patients with Crohn's Disease in Remission: is It a Feasible Long-term Strategy? Inflamm Bowel Dis 2014; 1-10.
13. Therneau TM,. A Package for Survival Analysis in S [Internet], 2014. Available at: http://cran.r-project.org/package=survival (accessed 11 January 2016).
14. Therneau Terry M, Grambsch Patricia M,. Modeling Survival Data: Extending the Cox Model. New York: Springer, 2000.
15. Viechtbauer W,. Conducting meta-analyses in R with the metafor package. J Stat Softw 2010; 36: 1-48.
16. The Cochrane Collaboration. Identifying and measuring heterogeneity, chapter 9.5.2. In:, Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, 2011; Available from: http://handbook.cochrane.org/chapter-9/9-5-2-identifying-and-measuring-heterogeneity.htm (Accessed 11 January 2016).
17. Cochran WG,. The combination of estimates from different experiments. Biometrics 1954; 10: 101.
18. Monterubbianesi R, Papi C, Kohn A,. P529. Maintenance of clinical remission in Crohn's disease patients after discontinuation of antiTNF agents: results from a single centre cohort. J Crohns Colitis 2015; 9: S345-S345.
19. Wynands J, Belbouab R, Candon S, et al,. 12-month follow-up after successful infliximab therapy in pediatric crohn disease. J Pediatr Gastroenterol Nutr 2008; 46: 293-8.
20. Louis E, Mary J-Y, Vernier-Massouille G, et al,. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70. e5; quiz e31.
21. Bortlik M, Duricova D, Machkova N, et al,. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation. Scand J Gastroenterol 2016; 51: 196-202.
22. Nunes T, Etchevers MJ, Domènech E, et al,. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era. Aliment Pharmacol Ther 2013; 38: 752-60.
23. Burisch J, Pedersen N, Cukovic-Cavka S, et al,. Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe-An ECCO-EpiCom study. J Crohns Colitis 2014; 8: 607-16.
24. Lunney PC, Kariyawasam VC, Wang RR, et al,. Smoking prevalence and its influence on disease course and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2015; 42: 61-70.
25. Brooks AJ, Sebastian S, Cross SS, Robinson K, Warren L, Wright A, et al,. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission. J Crohns Colitis 2015. pii: jjv000. http://ecco-jcc.oxfordjournals.org/content/early/2015/05/15/j.crohns.2014.09.007.long
26. Molander P, Färkkilä M, Salminen K, Kemppainen H, Blomster T, Koskela R, et al,. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis 2014; 20: 1021-8.
27. Dart RJ, Griffin N, Taylor K, Duncan J, Sastrillo M, Sanderson J, et al,. Reassessment of Crohn' s disease treated with at least 12 months of anti-TNF therapy: how likely is treatment withdrawal? Frontline Gastroenterol 2014; 5: 176-82.
28. Chauvin A, Le Thuaut A, Belhassan M, Le Baleur Y, Mesli F, Bastuji-Garin S, et al,. Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: a retrospective study. Dig Liver Dis 2014; 46: 695-700.
29. Molnár T, Lakatos PL, Farkas K, Nagy F, Szepes Z, Miheller P, et al,. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013; 37: 225-33.
30. Domènech E, Hinojosa J, Nos P, Garcia-Planella E, Cabré E, Bernal I, et al,. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment Pharmacol Ther 2005; 22: 1107-13.
31. Farkas K, Lakatos PL, Nagy F, Szepes Z, Miheller P, Papp M, et al,. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol 2013; 48: 1394-8.